Andrew Dold, DO
Infectious Disease · Dacula, GANPI 1073718516
Payments from drug & device makers
Across 2,715 payments — averaging $422.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Paratek Pharmaceuticals, Inc.$607K
- Insmed, Inc.$163K
- Viiv Healthcare Company$124K
- Melinta Therapeutics, LLC$86K
- Gilead$43K
- Merck$26K
- plus $99K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Paratek Pharmaceuticals, Inc. | 1,035 | $606,903 |
| Insmed, Inc. | 366 | $162,681 |
| Viiv Healthcare Company | 255 | $124,481 |
| Melinta Therapeutics, LLC | 264 | $85,549 |
| Gilead | 143 | $42,583 |
| Merck | 91 | $25,866 |
| Ferring Pharmaceuticals Inc. | 45 | $20,430 |
| AbbVie(2 entities) | 85 | $18,714 |
| Astellas Pharma US Inc | 58 | $18,618 |
| Cumberland Pharmaceuticals, Inc. | 28 | $10,739 |
| Tetraphase Pharmaceuticals, Inc. | 20 | $9,723 |
| Shionogi Inc | 28 | $9,616 |
| Pfizer | 55 | $4,182 |
| Johnson & Johnson(2 entities) | 74 | $1,212 |
| Cipla USA Inc. | 6 | $1,173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $1,121 |
| Regeneron Healthcare Solutions, Inc. | 2 | $1,013 |
| Theratechnologies Inc. | 21 | $441 |
| Grifols USA, LLC | 18 | $421 |
| La Jolla Pharmaceutical Company | 20 | $391 |
| Octapharma USA, Inc. | 9 | $296 |
| Janssen Products, LP | 4 | $189 |
| CSL Behring | 6 | $154 |
| Nabriva Therapeutics, PLC | 8 | $150 |
| EMD Serono, Inc. | 6 | $113 |
| ADMA Biomanufacturing LLC | 3 | $101 |
| Aimmune Therapeutics, Inc. | 3 | $83 |
| Napo Pharmaceuticals Inc | 3 | $73 |
| Mayne Pharma Commercial LLC | 4 | $70 |
| Angiodynamics, Inc. | 1 | $46 |
| Amgen | 2 | $34 |
| GRT US Holding, Inc. | 1 | $19 |
| Pharming Healthcare, Inc. | 1 | $16 |
How this compares
$1,147,204 in reported general payments places this provider in the 95th percentile of 260 infectious disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Dacula
- Mark MulliganAtlanta$4.6M
- Nadine RouphaelAtlanta$2.4M
- Leila HojatAtlanta$2.2M
- Kimberly WorkowskiAtlanta$2M
- Robin DretlerDecatur$1.8M
- Harold KatnerMacon$1.3M
- Jeffrey StephensMacon$1M
- Jose VazquezAugusta$967K
- Cheryl NewmanAugusta$945K
- Zandraetta Tims-CookAtlanta$878K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.